NCT05945810View on ClinicalTrials.gov

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 12, 2023

Primary Completion Date

August 28, 2023

Study Completion Date

August 28, 2023

Conditions
Atopic Dermatitis
Interventions
DRUG

TLL-018 extended-release tablet

50mg TLL-018 extended-release tablet QD

DRUG

TLL-018 immediate-release tablet

20mg TLL-018 immediate-release tablet BID

Trial Locations (1)

318000

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

Sponsors
All Listed Sponsors
lead

Hangzhou Highlightll Pharmaceutical Co., Ltd

INDUSTRY